Physician profile
Robert D Griffith
NPI 1619235355
$14,034.84
in general payments reported to CMS, 2019-2025
31 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $1,319 · 2021: $1,978 · 2022: $2,410 · 2023: $2,469 · 2024: $3,018 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,583.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,446.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $2,039.08 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $1,481.96 | 2019-2025 | |
| Lilly USA, LLC | $1,421.30 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,202.18 | 2019-2025 | |
| Ucb, INC. | $1,105.39 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $762.85 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $539.59 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $485.19 | 2022-2024 | Vtama |
| Pfizer INC. | $428.51 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $303.59 | 2021-2024 | Dupixent |
| Genentech USA, INC. | $257.76 | 2019-2021 | |
| Leo Pharma INC. | $229.47 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $190.96 | 2019-2024 | Otezla |
| Mayne Pharma Commercial LLC | $158.16 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $156.62 | 2025 | Vtama |
| Epi Health, LLC | $153.98 | 2022 | |
| Incyte Corporation | $144.22 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $103.13 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $85.39 | 2019-2025 | Nemluvio |
| Dermira, INC. | $60.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.09 | 2024 | Spevigo |
| Biofrontera INC. | $46.77 | 2022 | |
| Paratek Pharmaceuticals, INC. | $44.16 | 2022 | |
| Sensus Healthcare, INC. | $38.12 | 2021 | |
| Almirall LLC | $22.28 | 2024 | Seysara |
| Fresenius Kabi USA, LLC | $17.61 | 2024 | Idacio |
| Atricure, INC. | $15.15 | 2024 | |
| Celgene Corporation | $14.85 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.73 | 2019 | |
| Vyne Pharmaceuticals INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.